Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The largest trial yet for a potential COVID-19 vaccine began on Monday, as drug company Moderna began providing the first of an anticipated 30,000 volunteers with shots of its candidates. This is a blind trial, wherein some participants will get the vaccine and some will get placebos.

Moderna’s 30,000-participant Phase 3 COVID-19 vaccine trial kicks off in the U.S.

Moderna shares jumped after the biotech company announced it received an additional $472 million from the U.S. government to support the development of its potential coronavirus vaccine.

Moderna shares soar after U.S. ups funding for coronavirus vaccine by $472 million

SAP SE

Business software group SAP has been selected by Moderna to help distribute the potential COVID-19 vaccine that the U.S. pharmaceuticals company is developing, CEO Christian Klein said on Monday.

SAP picked by Moderna to help distribute COVID-19 vaccine candidate

Moderna has started a phase 3 trial for its coronavirus vaccine, as it races with AstraZeneca, Pfizer and others. MRNA stock jumped.

Moderna Starts Phase 3 Trial For Its Coronavirus Vaccine; MRNA Stock Jumps

Shares of Moderna Inc. MRNA, -2.81% gained 11.3% in premarket trading on Monday after the company said it started to dose participants in the Phase 3 trial for its experimental COVID-19 vaccine.

Moderna's stock rallies 11% as it begins Phase 3 trial for COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participants dosed in Phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273).

Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins

Shares of Moderna Inc. MRNA, -2.81% rallied 7.0% in premarket trading Monday, after the biopharmaceutical company announced over the weekend another $472 million commitment from the government to develop a COVID-19 vaccine.

Moderna's stock surges as new funding sets Phase 3 trial of COVID-19 vaccine candidate to start 'immediately'

Moderna said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority to support the development of its novel coronavirus vaccine.

Moderna gets further $472 million U.S. award for coronavirus vaccine development

Moderna Inc. (NASDAQ: MRNA) announced Sunday it is receiving another $472 million funding from President Donald Trump's administration to support late-stage clinical development of its coronavirus vaccine candidate, including an expanded phase 3 study.

Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development

Biotech company Moderna Inc. MRNA, -2.81% on Sunday announced the U.S. government has committed up to an additional $472 million to its efforts to develop a coronavirus vaccine.

Moderna secures another $472 million from U.S. for COVID-19 vaccine efforts

Moderna's contract with the government has been amended to include extra funding for a 30,000-patient phase 3 study.

Moderna Receives Additional $472 Million to Develop Coronavirus Vaccine

AstraZeneca

BioNTech SE

Inovio Pharmaceuticals

Novavax

Pfizer

Let's take a look at what's happened so far and what's on the horizon.

Here's Your Guide to the Coronavirus Vaccine Leaders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces expansion of BARDA agreement to support larger Phase 3 program for vaccine (mRNA-1273) against COVID-19.

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

One coronavirus vaccine candidate in phase 3 testing might have the best shot at achieving commercial success.

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

Johnson & Johnson

The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

Vaxart

COVID-19 vaccines might not be the moneymakers investors are hoping for.

Why Moderna, Vaxart, Inovio, and BioNTech Stocks Dropped Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Statement from Moderna on Patent Trial and Appeal Board (PTAB) ruling.

Statement from Moderna on Patent Trial and Appeal Board (PTAB) Ruling

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session.

How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program

Shares of Moderna Inc. MRNA, -9.48% were down 4.7% in premarket trading on Friday, the day after the U.S.

Moderna's stock falls the day after 'disappointing' patent ruling

Moderna Inc (NASDAQ: MRNA) has lost the bid to invalidate a key patent related to the development of several of its next-generation vaccines, including one meant for coronavirus, to Arbutus Biopharma Corp (NASDAQ: ABUS), Reuters reported.

Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent

Shares of Moderna Inc fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines, including a coronavirus vaccine.

Moderna loses challenge to Arbutus patent on vaccine technology

Moderna stock tumbled late Thursday after the biotech lost a patent battle that could jeopardize the financial future of its coronavirus vaccine. It was unsuccessful in a patent challenge.

Moderna Dives On Patent Battle That Could Jeopardize Coronavirus Vaccine

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine in development — mRNA-1273 — continues to inspire confidence among sell-side analysts.

Moderna Analyst Says Odds Are Good For COVID-19 Vaccine Approval, But Valuation Overcooked

You have to look at more than just their COVID-19 programs.

Better Coronavirus Stock: AstraZeneca vs. Moderna

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process today announced that it is collaborating with Moderna, Inc. (Nasdaq: MRNA) to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

News for Moderna Stock (MRNA)